Medullary Thyroid Cancer
Debio 1124 is a second-generation peptide analogue of minigastrin, coupled to the isotope 177Lutetium. This compound belongs to the emerging class of Peptide Receptor Radionuclide Therapies (PRRT) and has been designed to selectively deliver radiotherapy to tumor cells expressing the Cholecystokinin B Receptor (CCK2R). Importantly, as the compound can also be used as a sensitive diagnostic tool, an initial imaging step allows the selection of patients whose tumor expresses the target receptor and so are expected to benefit from this innovative treatment.
This theranostic (therapeutic and diagnostic) compound is currently being developed in advanced Medullary Thyroid Cancer (MTC) and will be further investigated in other tumor types expressing CCK2R.
October 11, 2018
Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic…